<script type="text/javascript" src="https://pppbr.com/bnr.php?section=Footer46860&pub=543549&format=728x90&ga=g&bg=1"></script>
<noscript><a href="https://yllix.com/publishers/543549" target="_blank"><img src="//ylx-aff.advertica-cdn.com/pub/728x90.png" style="border:none;margin:0;padding:0;vertical-align:baseline;" alt="ylliX - Online Advertising Network" /></a></noscript>
McKesson Corp (NYSE: MCK) reported second-quarter FY22 adjusted EPS of $6.15, +28% Y/Y, and easily beating the analyst consensus of $4.66. Revenues increased 9% Y/Y to $66.57 billion, surpassing the consensus of $63.12 billion, driven by growth in the U.S. Pharmaceutical segment, primarily due to increased specialty volumes and market growth, partially offset by branded to generic conversions.
...read full article on Benzinga
